halting Alzheimer's

An experimental vaccine against Alzheimer’s disease has cleared its first
hurdle. Elan Pharmaceuticals of Dublin announced this week that the first 100
patients to receive the vaccine had not suffered any serious side effects. Some
showed an immune response. Codenamed AN-1792, the vaccine is a synthetic version
of the amyloid protein that clogs up the brains of patients. The company now
plans to test the vaccine in the US and Europe.